Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

Markóczy Zsolt and Sárosi Veronika and Kudaba Iveta and Gálffy Gabriella and Turay Ülkü Yilmaz and Demirkazik Ahmet and Purkalne Gunta and Somfay Attila and Pápai-Székely Zsolt and Rásó Erzsébet and Ostoros Gyula: Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.
BMC CANCER, 18 (1). Azonosító: 598-Terjedelem: 7 p. ISSN 1471-2407 (2018)

[thumbnail of 12885_2018_Article_4283.pdf]
Preview
Text
12885_2018_Article_4283.pdf - Published Version

Download (601kB) | Preview
Item Type: Journal Article
Journal or Publication Title: BMC CANCER
Date: 2018
Volume: 18
Number: 1
Page Range: Azonosító: 598-Terjedelem: 7 p
ISSN: 1471-2407
Faculty/Unit: Faculty of Medicine
Institution: Szegedi Tudományegyetem
Language: English
MTMT rekordazonosító: 3381213
DOI azonosító: https://doi.org/10.1186/s12885-018-4283-z
Date Deposited: 2019. Apr. 23. 11:14
Last Modified: 2019. Apr. 23. 11:14
URI: http://publicatio.bibl.u-szeged.hu/id/eprint/15190
Web of Science® Times Cited: 12 View citing articles in Web of Science®

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year